Zhongchao Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsZhongchao Inc. is a Cayman Islands-incorporated healthcare information and education services company operating in China and listed on Nasdaq under the ticker ZCMD.
What they do
Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company operates through subsidiaries and consolidated affiliated entities, offering online and offline medical education, conference services, and related digital solutions to healthcare professionals and institutions. Its Class A Ordinary Shares trade on the Nasdaq Stock Market LLC.
Revenue drivers
- Healthcare education and training services — The company generates revenue by providing continuing medical education, training programs, and conferences to healthcare professionals and institutions in China.
- Digital healthcare information services — Revenue is derived from online platforms and digital tools that deliver medical information, educational content, and related services.
- Conference and event services — The company organizes medical conferences, seminars, and workshops, earning fees from participants and sponsors.
Recent performance
Annual revenue declined to $11.4 million in 2025 from $15.9 million in 2024 and $19.4 million in 2023. The company reported a net loss of $6.3 million in 2025, compared to a net loss of $0.6 million in 2024 and a net loss of $11.3 million in 2023. Diluted EPS was negative $1.85 in 2025, versus negative $0.99 in 2024. Operating cash flow was positive $0.8 million in 2025, a turnaround from negative $1.5 million in 2024. As of December 31, 2025, total assets were $24.1 million, total liabilities $1.5 million, and shareholder equity $18.6 million.
Strategy
The company's 20-F does not provide detailed strategic initiatives in the excerpted sections. Management focuses on providing healthcare education and information services in China. The company may continue to invest in digital platforms and expand its service offerings. No specific forward-looking investments or priorities were disclosed in the available text.
Risks
- Declining revenue — Revenue has fallen for two consecutive years, from $19.4 million in 2023 to $11.4 million in 2025, indicating challenges in maintaining or growing the business.
- Net losses — The company incurred a net loss of $6.3 million in 2025, following a net loss of $0.6 million in 2024, raising concerns about profitability.
- Negative operating cash flow history — Operating cash flow was negative in 2022 and 2024, though it turned positive in 2025, highlighting potential volatility in cash generation.
- Foreign private issuer and China operations — As a Cayman Islands company with operations in China, Zhongchao faces regulatory, political, and economic risks specific to the PRC, including potential changes in laws affecting foreign investments and data security.
Outlook
The 20-F excerpt does not include management's specific outlook or guidance for future periods. The company's ability to return to revenue growth and achieve profitability will depend on its execution in the Chinese healthcare education market. Investors should monitor upcoming filings for strategic updates.